Charles River Laboratories (CRL)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$313.02-4.07%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · CRL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.7% |
| Our one-year growth estimate | diamond | 0.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 13.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers · Company calendar date is not available
CRL — officer change
Dated 2026-05-11
The filing is about the approval of a new long-term incentive plan, not a management change.
Why it matters: Non-GAAP margin fell year over year in Q2 as study costs rose. A recovery would show that recent demand gains are reaching profits.
Supportive ifQ3 non-GAAP operating margin is above 22.1%, its level in Q2 2025.
Worry ifQ3 non-GAAP operating margin is below 20.5%, its Q2 2026 level.
Why it matters: Apollo aims to make client work easier and deepen client ties. More users would show that clients are taking up the platform.
Supportive ifCRL reports more than 20,000 Apollo users and confirms added tools or services for clients.
Worry ifApollo user count stays at or below 18,000, or CRL reports no new client tools or services.
Why it matters: CRL named bioanalysis as a key investment area and set a 2030 revenue goal. Results can show whether the business is on that path.
Supportive ifAnnual bioanalysis revenue growth reaches a high single-digit rate. The business stays on track for about $450 million in 2030.
Worry ifAnnual bioanalysis revenue growth falls below 5%, or CRL lowers its $450 million 2030 goal.
Why it matters: DSA demand strengthened in Q2, and regulated safety study volume drove growth. Another strong quarter would support that trend.
Supportive ifQ3 DSA organic revenue grows year over year, and net book-to-bill stays above 1.0.
Worry ifQ3 DSA organic revenue falls year over year, or net book-to-bill drops below 1.0.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$130 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $427 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,388 loss on $10,000 · 33.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CRL set a goal to save over $300 million from 2027 through 2030. Reported savings would test progress on its efficiency plan.
Supportive ifCRL reports at least $75 million in yearly savings by the end of 2027. Savings total over $300 million through 2030.
Worry ifCRL reports less than $75 million in annual savings by the end of 2027, or lowers the over-$300-million goal.